An oncology pharma used Owkin's K Pro and MOSAIC data to triage bispecific ADC candidates in silico.

Heterogeneous, rarely tumor-specific antigens make antibody-drug conjugate targeting hard in solid tumors. Owkin applied K Pro with MOSAIC data and ADC tools for spatial tumor mapping and target pairing, then validated in vitro. The page states the bispecific OKN3201 outperformed both monospecific ADCs in the wet lab and that in-silico triage replaces costly lab cycles.

Owkin is a French AI company building biology models and the K Pro AI Scientist, working with pharma on drug positioning, trial design and pathology diagnostics.

This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.